Abstract Background Coronavirus disease 2019 (Covid-19) is associated with immune
dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of …

ABSTRACT BACKGROUND COVID-19 is associated with immune dysregulation and
hyperinflammation. Tocilizumab is an anti–interleukin-6 receptor antibody. METHODS …

Abstract Background Coronavirus disease 2019 (Covid-19) pneumonia is often associated
with hyperinflammation. Despite the disproportionate incidence of Covid-19 among …

Tocilizumab, an anti-interleukin-6 receptor, administrated during the right timeframe may be
beneficial against coronavirus-disease-2019 (COVID-19) pneumonia. All patients admitted …

Background Pneumonia with respiratory failure represents the main cause of death in
COVID-19, where hyper inflammation plays an important role in lung damage. This study …

Background The efficacy of interleukin-6 receptor blockade in hospitalized patients with
coronavirus disease 2019 (Covid-19) who are not receiving mechanical ventilation is …

Importance The coronavirus disease 2019 (COVID-19) pandemic is threatening billions of
people worldwide. Tocilizumab has shown promising results in retrospective studies in …

Background To date, only dexamethasone has been shown to reduce mortality in
coronavirus disease-19 (COVID-19) patients. Tocilizumab has been recently added to the …

Background In COVACTA, a randomised, placebo-controlled trial in patients hospitalised
with coronavirus disease-19 (COVID-19), tocilizumab did not improve 28-day mortality, but …

Background High levels of serum interleukin-6 (IL-6) correlate with disease severity in
COVID-19. We hypothesized that tocilizumab (a recombinant humanized anti-IL-6 receptor) …